The study is designed as a single-center,open-label,phase 1 dose-escalation study to assess the safety,tolerability,pharmacokinetics, and anti-tumor efficacy of OPB-31121 in patients with relapsed or refractory NHL or MM.~To investigate the safety and tolerability of OPB-31121 following repeated oral administration of OPB-31121 in patients NHL or MM~To determine the potential dose-limiting toxicities and maximum-tolerated dose in patients treated with OPB-31121~To determine the pharmacokinetics and anti-tumor efficacy of OPB-31121 in patients
To investigate the safety and tolerability of OPB-31121 following repeated oral administration of OPB-31121 in patients Non-Hodgkin's Lymphoma(NHL) or Multiple Myeloma(MM)~To determine the potential dose-limiting toxicities and maximum-tolerated dose in patients treated with OPB-31121~To determine the pharmacokinetics and anti-tumor efficacy of OPB-31121 in patients